Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Pfizer Inc (PFE) Price & Performance

iShares JPMorgan USD Emerging Markets Bond ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares JPMorgan USD Emerging Markets Bond ETF vs Pfizer Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.

EMBPFE
Sector
Fixed IncomeHealth
52-Week High
$97.74$28.56
52-Week Low
$92.95$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares JPMorgan USD Emerging Markets Bond ETF

EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.

Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.

Pfizer Inc

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares JPMorgan USD Emerging Markets Bond ETF

EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.

Read more on EMB

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE